Literature DB >> 23764276

Ozurdex in the management of the macular edema following retinal vein occlusion in clinical practice.

Frederic Matonti1, Franck Meyer, Sebastien Guigou, Tony Barthelemy, Stephane Dumas, Frederic Gobert, Christian Hajjar, Pierre Y Merite, Eric Parrat, Herve Rouhette, Stephan Pommier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23764276     DOI： 10.1111/aos.12190

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN： 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  5 in total

1.  Anatomical and functional recurrence after dexamethasone intravitreal implants: a 6-month prospective study.

Authors:  V Fortoul; P Denis; L Kodjikian
Journal:  Eye (Lond)       Date:  2015-03-20       Impact factor: 3.775

2.  Retinal venous pressure in the non-affected eye of patients with retinal vein occlusions.

Authors:  Maneli Mozaffarieh; M Bärtschi; P B Henrich; A Schoetzau; J Flammer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-28       Impact factor: 3.117

3.  Outcome of intravitreal dexamethasone implant for the treatment of ranibizumab-resistant macular edema secondary to retinal vein occlusion.

Authors:  Kleanthis Manousaridis; Silvia Peter; Stefan Mennel
Journal:  Int Ophthalmol       Date:  2016-04-04       Impact factor: 2.031

Review 4.  Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment.

Authors:  Justus G Garweg; Souska Zandi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-13       Impact factor: 3.117

5.  Comparison of treatment response to intravitreal injection of triamcinolone, bevacizumab and combined form in patients with central retinal vein occlusion: A randomized clinical trial.

Authors:  Ghader Motarjemizadeh; Miaad Rajabzadeh; Naser Samadi Aidenloo; Rohollah Valizadeh
Journal:  Electron Physician       Date:  2017-08-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.